IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

Chemotherapeutic Candidate Inducing Immunological Death of Human Tumor Cell Lines

  • Oh, Su-Jin (Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ryu, Chung-Kyu (College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University) ;
  • Choi, In-Hak (Department of Microbiology & Immunology, Inje University College of Medicine) ;
  • Baek, So-Young (Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Hyun-Ah (Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2012.03.10
  • Accepted : 2012.03.28
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The immunological death induction by EY-6 on the human tumor cell lines was screened. Human colon carcinoma (HCT15, HCT116), gastric carcinoma (MKN74, SNU668), and myeloma (KMS20, KMS26, KMS34) cells were died by EY-6 treatment with dose-dependent manner. CRT expression, a typical marker for the immunological death, was increased on the EY-6-treated colorectal and gastric cancer cells. Interestingly, the effects on the myeloma cell lines were complicated showing cell line dependent differential modulation. Cytokine secretion from the EY-6 treated tumor cells were dose and cell-dependent. IFN-${\gamma}$ and IL-12 secretion was increased in the treated cells (200% to over 1000% of non-treated control), except HCT116, SNU668 and KMS26 cells which their secretion was declined by EY-6. Data suggest the potential of EY-6 as a new type of immuno-chemotherapeutics inducing tumor-specific cell death. Further studies are planned to confirm the efficacy of EY-6 including in vivo study.

Keywords

References

  1. Oh SJ, Ryu CK, Baek SY, Lee H: Cellular mechanism of newly synthesized indoledione derivative-induced immunological death of tumor cell. Immune Netw 11;383-389, 2011. https://doi.org/10.4110/in.2011.11.6.383
  2. Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G: Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from 􀙘silent􀙙 to immunogenic. Cancer Res 67;7941-7944, 2007. https://doi.org/10.1158/0008-5472.CAN-07-1622
  3. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G: Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 16;3100-3104, 2010. https://doi.org/10.1158/1078-0432.CCR-09-2891
  4. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, Yuan J, Zitvogel L, Madeo F, Williams DB, Kroemer G: Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28;578-590, 2009. https://doi.org/10.1038/emboj.2009.1
  5. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13;54-61, 2007. https://doi.org/10.1038/nm1523
  6. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM: Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123;321-334, 2005. https://doi.org/10.1016/j.cell.2005.08.032
  7. Lee H, Baek S, Joe SJ, Pyo SN: Modulation of IFN-gamma production by TNF-alpha in macrophages from the tumor environment: significance as an angiogenic switch. Int Immunopharmacol 6;71-78, 2006. https://doi.org/10.1016/j.intimp.2005.08.010
  8. Esumi N, Hunt B, Itaya T, Frost P: Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res 51;1185-1189, 1991.
  9. Janelidze S, Bexell D, Badn W, Darabi A, Smith KE, Fritzell S, Gunnarsson S, Milos P, Bengzon J, Salford LG, Siesjö P, Visse E: Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas. J Immunother 32;593-601, 2009. https://doi.org/10.1097/CJI.0b013e3181a95148

Cited by

  1. Characterization of antiproliferative potential and biological targets of a copper compound containing 4′-phenyl terpyridine vol.20, pp.6, 2012, https://doi.org/10.1007/s00775-015-1277-z